Daiichi Sankyo and Biota Bring Next-gen Flu Drug To Japan; Continue Search For Western Partner
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Daiichi Sankyo has received marketing and manufacturing approval in Japan for its second-generation long-acting neuraminidase inhibitor Inavir (laninamivir), bringing encouraging news to Daiichi Sankyo and Australian partner Biota, which have faced delays in snagging an ex-Japan partner for the drug